National Attorneys Launch Invokana Ketoacidosis Lawsuit Center
The Onder Law Firm, a national pharmaceutical and medical device law firm announces a new website which provides timely Invokana lawsuit news for claims relating to allegations of blood acid problems,...(PRWeb July 07, 2015)Read the full story at http://www.prweb.com/releases/invokana-attorneys/kidney-lawsuit/prweb12831727.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 8, 2015 Category: Pharmaceuticals Source Type: news
FDA Safety Warning For Invokana, Other SGLT2 Inhibitor Type 2 Diabetes...
The new Invokana website was launched to provide the public with updated information on the potential association between the use of SGLT2 inhibitors like Invokana and diabetic ketoacidosis.(PRWeb June 11, 2015)Read the full story at http://www.prweb.com/releases/invokana-ketoacidosis/invokana-lawsuit/prweb12783059.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 12, 2015 Category: Pharmaceuticals Source Type: news
Three Diabetes Drugs Linked to Ketoacidosis, FDA Warns
(MedPage Today) -- FDA targets SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 16, 2015 Category: Cardiology Source Type: news
Janssen India launches diabetes treatment drug
Taken orally once a day, Invokana belongs to a new class of medications which work in a completely different way to other classes of type 2 diabetes medications. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 23, 2015 Category: Pharmaceuticals Source Type: news
Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven
As in the first dossier assessment of canagliflozin, the drug manufacturer provided no suitable data for the fixed combination with metformin either. Therefore, no added benefit of canagliflozin plus metformin has been demonstrated for type 2 diabetes care. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 21, 2014 Category: Science Source Type: news
Type 2 diabetes: Added benefit of canagliflozin plus metformin is not proven
(Institute for Quality and Efficiency in Health Care) As in the first dossier assessment of canagliflozin, the drug manufacturer provided no suitable data for the fixed combination with metformin either. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 21, 2014 Category: Global & Universal Source Type: news
FDA approves canagliflozin/metformin combination (Clinical Endocrinology News, 11 August)
The Food and Drug Administration has approved Invokamet, a fixed-dose combination of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, and metformin, for type 2 diabetes. The drug will marketed in the USA by Janssen Pharmaceuticals.
Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 13, 2014 Category: Endocrinology Source Type: news
FDA approves canagliflozin/metformin combination (Clinical Endocrinology News, 11 August 2014)
The Food and Drug Administration has approved Invokamet, a fixed-dose combination of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, and metformin, for type 2 diabetes. The drug will marketed in the USA by Janssen Pharmaceuticals.
Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 13, 2014 Category: Endocrinology Source Type: news
Canagliflozin/Metformin Combo Finally Approved in USCanagliflozin/Metformin Combo Finally Approved in US
First approval of an SGLT2 inhibitor/metformin combination in the US is Janssen's canagliflozin. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 11, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
NICE issues positive final guidance for INVOKANA®
Janssen has welcomed the publication of Final Guidance from the National Institute for Health and Care Excellence for canagliflozin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 26, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes Canagliflozin Invokana janssen Latest News nice type 2 diabetes Source Type: news
Type 2 diabetes mellitus: Added benefit of canagliflozin is not proven
(Institute for Quality and Efficiency in Health Care) In its dossier, the drug manufacturer presented no suitable data for canagliflozin -- neither as monotherapy nor in combination with metformin, sulfonylurea or insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2014 Category: Global & Universal Source Type: news
Health Canada approves Janssen’s type 2 diabetes mellitus medication
Johnson & Johnson subsidiary Janssen has announced Health Canada's approval for Invokana (canagliflozin), indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 26, 2014 Category: Pharmaceuticals Source Type: news
Invokana Monotherapy Promising for T2D Control
LAS VEGAS (MedPage Today) -- The SGLT2 inhibitor canagliflozin (Invokana) may be effective as monotherapy in type 2 diabetes patients who fail to control their disease with diet and exercise, researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 20, 2014 Category: Cardiology Source Type: news
Vokanamet: Metformin/Canagliflozin Combo Approved in EUVokanamet: Metformin/Canagliflozin Combo Approved in EU
A single pill combining metformin with the SGLT-2 inhibitor canagliflozin, named Vokanamet, has been approved for the treatment of type 2 diabetes in Europe. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 29, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
New Diabetes Drugs Invokana and Vipidia Launched in UKNew Diabetes Drugs Invokana and Vipidia Launched in UK
Two new oral drugs for the treatment of type 2 diabetes have been launched in the United Kingdom: the SGLT2 inhibitor canagliflozin and the DPP-4 inhibitor alogliptin. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 28, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
